Purdue University

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Retrieved on: 
Monday, April 8, 2024
Shingles, Editas Medicine, Regulatory affairs, Bristol Myers Squibb, Doctor of Philosophy, MBA, Rutgers University, Immunization, Johnson & Johnson, Allergan, RAC, Vaccine, Purdue University, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.

Key Points: 
  • SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.
  • “We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.”
    Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally.
  • “I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li.
  • Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer.

Gov. Holcomb, IEDC announce generational multi-billion-dollar investment to make Indiana leader in semiconductor packaging

Retrieved on: 
Wednesday, April 3, 2024
CHIPS, Technology policy, Incentive, Naval Surface Warfare Center, Carbon, Commerce, Purdue Research Park, Investment, Policy, HBM, Duke Energy, Partnership, Research, News, AI, Architecture, Semiconductor, NSWC, South Korea, SK Hynix, Dynamic random-access memory, Engineering, Assistant, Recycling, DRAM, Organic, Silicon, Graphics processing unit, United States Commercial Service, Ecosystem, Purdue University, Renewable energy

The facility will also develop future generations of chips and house an advanced packaging R&D line.

Key Points: 
  • The facility will also develop future generations of chips and house an advanced packaging R&D line.
  • “We are excited to build a state-of-the-art advanced packaging facility in Indiana,” said SK hynix CEO Kwak Noh-Jung.
  • “We believe this project will lay the foundation for a new Silicon Heartland; a semiconductor ecosystem centered in the Midwest Triangle.
  • The IEDC also committed up to $45 million through the Industrial Development Grant Fund to support infrastructure improvements surrounding the new plant.

Ultimate Medical Academy Celebrates Commencement for Thousands of Healthcare Student Graduates

Retrieved on: 
Monday, April 1, 2024
Friends, Marriage, Growth, Medicine, Education, Bureau, Interview, Careers New Zealand, Student, Ultimate Medical Academy, Yuengling Center, Medical assistant, Hospital, UMA, Purdue University, Nursing

The live-streamed ceremony honored students who completed or will complete their programs between October 23, 2023, and April 28, 2024.

Key Points: 
  • The live-streamed ceremony honored students who completed or will complete their programs between October 23, 2023, and April 28, 2024.
  • The event was live-streamed so UMA graduates, their friends and family members across the nation were able to join the celebration.
  • While commencement signifies the culmination of academic endeavors, UMA remains committed to supporting its graduates beyond graduation day.
  • These invaluable services extend throughout the professional journeys of all UMA alumni, ensuring their continued success in the evolving healthcare landscape.

DRYWORLD Marches Into the Madness – Announces Partnership With Purdue Point Guard Braden Smith

Retrieved on: 
Thursday, March 28, 2024
Boilermaker, E-commerce, AP, DeAngelo, NCAA, Partnership, Big Ten Conference, Westfield High School, Smith, D'Angelo, Final four, Athlete, OTC, Michigan State University, Maestro, Collection, NIL, Purdue University, Online shopping

SANTA BARBARA, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- DRYWORLD Brands Inc. (OTC: IBGR), a premium performance sports brand, is pleased to announce its partnership with Purdue University star point guard Braden Smith, through a one-year Name Image and Likeness (NIL) agreement making DRYWORLD his official apparel brand and merchandise partner.

Key Points: 
  • SANTA BARBARA, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- DRYWORLD Brands Inc. (OTC: IBGR), a premium performance sports brand, is pleased to announce its partnership with Purdue University star point guard Braden Smith, through a one-year Name Image and Likeness (NIL) agreement making DRYWORLD his official apparel brand and merchandise partner.
  • The collaboration includes a comprehensive merchandise offering and dedicated eCommerce support for fan merchandise sales, set to launch during March Madness 2024.
  • “We're fired up to back Braden, offering him and fans premium basketball gear for March Madness and beyond,” stated DRYWORLD CEO Brian McKenzie.
  • His abilities have garnered national attention, with Smith recently named a finalist for the Bob Cousy Point Guard of The Year and as an Honorable Mention for the AP All-America team.

Corvias Property Management Nationally Recognized for Resident Satisfaction

Retrieved on: 
Tuesday, April 9, 2024
Construction & Property, Defense, Military, Other Defense, University, Veterans, Education, Residential Building & Real Estate, Housing, Lower Coastal Plain (Georgia), University of Montevallo, Abraham Baldwin Agricultural College, Multimedia, Silver Wings, College of Coastal Georgia, Purdue University, Auction

Recognized for delivering exceptional operational and maintenance services to residents across its military and higher education portfolios, Corvias Property Management was awarded the 2023 SatisFacts “Company Award for 2023.” Seven military installations and five higher education institutions received resident satisfaction awards for earning high survey scores for the management of its housing communities.

Key Points: 
  • Recognized for delivering exceptional operational and maintenance services to residents across its military and higher education portfolios, Corvias Property Management was awarded the 2023 SatisFacts “Company Award for 2023.” Seven military installations and five higher education institutions received resident satisfaction awards for earning high survey scores for the management of its housing communities.
  • (Photo: Business Wire)
    “These awards are a testament to our team’s commitment and the strength of our partnerships,” said Chris Wilson, chief executive officer of Corvias.
  • Corvias provides operations and maintenance services to more than 72,000 residents across its military and higher education portfolios.
  • Across 10 U.S. states, Corvias Property Management maintains 42,000 residential units across seven military installations and 15 universities.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Liberation Labs Taps Biotech Biomanufacturing Veteran Rhys Dale to Assist with Development & Operations of Flagship Facility

Retrieved on: 
Wednesday, March 13, 2024
DSP, Dale, University, Food, Engineering, CPG, Life, Process engineering, Earlham College, CMO, Economics, Purdue University, Management

RICHMOND, Ind., March 13, 2024 (GLOBE NEWSWIRE) -- Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond.

Key Points: 
  • RICHMOND, Ind., March 13, 2024 (GLOBE NEWSWIRE) -- Liberation Labs has appointed Rhys Dale as Site Director for its flagship biomanufacturing facility currently being constructed in Richmond.
  • Dale has deep expertise in process conceptualization/design, technology development/scale-up, techno-economic process modeling, permitting, project development, and manufacturing.
  • Liberation Labs is currently constructing a commercial-scale, purpose-built, precision fermentation biomanufacturing facility with a capacity of 600,000 liters and a fully dedicated downstream process (DSP).
  • “Rhys is a proven leader in scaling biotechnology through biomanufacturing development and operations, and it’s great to have him on board at this time in the project’s lifecycle,” said Mark Warner, co-founder and CEO of Liberation Labs.

MAX Service Group Names Mike Roszkowski as New President

Retrieved on: 
Monday, April 1, 2024
Professional Services, Small Business, HVAC, Other Construction & Property, Residential Building & Real Estate, Manufacturing, Construction & Property, MAX, Culture, Heat, Organization, Growth, Purdue University, Management

MAX Service Group, which operates five leading heating, cooling, plumbing and electrical companies serving the Midwest, is proud to announce Mike Roszkowski as its new President.

Key Points: 
  • MAX Service Group, which operates five leading heating, cooling, plumbing and electrical companies serving the Midwest, is proud to announce Mike Roszkowski as its new President.
  • Roszkowski, who previously served as Vice President of Operations for MAX Service Group has a long history of leadership experience with various roles within the mechanical and HVAC fields.
  • “I’m honored to take the baton and lead MAX Service Group,” said Roszkowski.
  • “The MAX Service Group brands are all respected leaders in their markets, and I’m grateful for the opportunity to continue building those reputations.

Surf Air Mobility Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2023

Retrieved on: 
Thursday, March 28, 2024
Air, Transport, Aerospace, Manufacturing, Aircraft, Microsoft, MOU, ROI, Southern Airways, Surf Air Mobility, Growth, Garmin, Partnership, Insurance, Cessna 208 Caravan, Auric Air, GAAP, Surf Air, Purdue University, Airline

Surf Air Mobility Inc. (NYSE: SRFM), a leading regional air mobility platform, today reported its fourth quarter and full year results.

Key Points: 
  • Surf Air Mobility Inc. (NYSE: SRFM), a leading regional air mobility platform, today reported its fourth quarter and full year results.
  • Please visit the Surf Air Mobility investor relations website at investors.surfair.com for more information and to listen to the accompanying earnings call at 5:00 pm eastern time.
  • Pro forma revenue of $27.4 million for fourth quarter 2023, compared to $27.7 million for the same period of the prior year.
  • Surf Air Mobility will provide full-year 2024 guidance at its Investor Day to be held on June 7, 2024, at the New York Stock Exchange.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.